• August 5, 2022  

    FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Bookmark

    George Lundberg, MD

    The ASCO Post reports on the U.S. Food And Drug Administration (FDA)’s recent approval of two new treatments for advanced, unresectable squamous cell carcinoma of the esophagus.

    .

  • August 5, 2022  

    Summary of Kidney Cancer Highlights from ASCO GU 2022 Bookmark

    George Lundberg, MD

    This article from the International Kidney Cancer Coalition (IKCC) outlines updates on treatment options for renal cell carcinoma as presented at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium.

    .

  • August 5, 2022  

    Recent Advances in Systemic Therapy for Hepatocellular Carcinoma Bookmark

    George Lundberg, MD

    This review article in the academic research journal Biomarker Research discusses how combining immunotherapy and targeted therapies provides new hope for people with hepatocellular carcinoma.

    .

  • August 5, 2022  

    Treatment Approaches for Advanced Hepatocellular Carcinoma: Insight From the 2022 Gastrointestinal Cancers Symposium Bookmark

    George Lundberg, MD

    In this article for Cancer Therapy Advisor, Dr. Shaalan Beg shares updates from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium on treatments for advanced hepatocellular carcinoma.

    .

  • July 30, 2022  

    Deciphering the Elusive Origin and Pathways of Brain Metastases Bookmark

    George Lundberg, MD

    The most common brain tumors are other types of cancer that have spread (or “metastasized”) to the brain from a primary site elsewhere in the body. And, the genomic makeup of the brain metastases may not be the same as the primary cancer. An article from The ASCO Post discusses what this means for treatment.

    .

  • July 30, 2022  

    Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer Bookmark

    George Lundberg, MD

    Cancer that spreads to the brain is very difficult to treat, especially because of the blood-brain barrier. This article from The ASCO Post describes one promising new treatment.

    .

  • July 25, 2022  

    How an Emory Professor would Treat Her Own Advanced Endometrial Cancer

    With: Jane Meisel, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Jane Meisel, MD, how she would handle her own advanced endometrial cancer. Dr. Meisel is Associate Professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University in Atlanta, GA. Curious Dr. George: Please consider a hypothetical… Read more »

  • July 13, 2022  

    Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification, and Management Bookmark

    George Lundberg, MD

    Written for oncology healthcare professionals, this article from the American Journal of Hematology covers the best new therapies for chronic myelomonocytic leukemia in 2022.

    .

  • July 13, 2022  

    Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022 Bookmark

    George Lundberg, MD

    Written for oncology healthcare professionals, this article from the ASCO Educational Book covers targeted therapies and immunotherapies that are now available to improve the prospects of people with acute myeloid leukemia.

    .

  • July 13, 2022  

    10 Years in CLL: Top Advances From 2012-2022 Bookmark

    George Lundberg, MD

    Published by Targeted Therapies in Oncology for healthcare professionals, this article outlines how novel targeted therapies have largely replaced chemotherapy and prolonged life greatly for people with chronic lymphocytic leukemia (CLL).

    .